Register Login

Mirum Pharmaceuticals Inc (MIRM)

(90% Positive) Mirum Pharmaceuticals Inc (MIRM) Announces Enrollment Update for year Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 7:58 p.m.

    📋 Mirum Pharmaceuticals Inc (MIRM) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:40:29

    Event Type: Clinical Trial Update

    Event Details:

    Mirum Pharmaceuticals Inc (MIRM) Announces Clinical Trial Update Mirum Pharmaceuticals Inc (MIRM) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: year, brelovitug
    • Diseases/Conditions: chronic hepatitis delta virus (HDV)
    • Clinical Stage: Phase 3
    • Collaboration: HDV
    • Updated Timeline: Q4 2026, Q2 2026
      • expected in H2 2026
      • expected in Q2 2026
      • anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025

    🔬 Clinical Development Pipeline (Mirum Pharmaceuticals Inc):

    Product Type Development Stage Therapeutic Area Source
    Ursodeoxycholic Acid DRUG Phase PHASE2 PBC ClinicalTrials.gov
    Livmarli Oral Product DRUG Phase PHASE4 Alagille Syndrome ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Fragile X Syndrome ClinicalTrials.gov
    Volixibat DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov
    Livmarli DRUG Preclinical Alagille Syndrome ClinicalTrials.gov
    Cholbam DRUG Preclinical Bile Acid Synthesis Disorders ClinicalTrials.gov
    Low dose of MRM-3379 Open-Label DRUG Phase PHASE2 Fragile X Syndrome ClinicalTrials.gov
    High dose of MRM-3379 DRUG Phase PHASE2 Fragile X Syndrome ClinicalTrials.gov
    Middle Dose of MRM-3379 DRUG Phase PHASE2 Fragile X Syndrome ClinicalTrials.gov
    Low dose of MRM-3379 DRUG Phase PHASE2 Fragile X Syndrome ClinicalTrials.gov
    Maralixibat DRUG Phase PHASE3 Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) ClinicalTrials.gov
    LUM001 DRUG Phase PHASE2 Primary Sclerosing Cholangitis (PSC) ClinicalTrials.gov
    SHP626 DRUG Phase PHASE1 Non-Alcoholic Steatohepatitis ClinicalTrials.gov
    5.95 μCi RAD RADIATION Phase PHASE1 Non-Alcoholic Steatohepatitis ClinicalTrials.gov
    LUM001 (Maralixibat) DRUG Phase PHASE2 Alagille Syndrome ClinicalTrials.gov
    Cholic Acids DRUG Phase PHASE3 Infantile Refsum's Disease ClinicalTrials.gov
    Cholic Acid DRUG Phase PHASE3 Bile Acid Synthesis Defect ClinicalTrials.gov
    CDCA Weight-Based Dose TID DRUG Phase PHASE3 CTX ClinicalTrials.gov
    Rescue Medication CDCA 250 mg TID DRUG Phase PHASE3 CTX ClinicalTrials.gov
    Open-Label CDCA 250 mg TID DRUG Phase PHASE3 CTX ClinicalTrials.gov
    Blinded CDCA 250 mg TID DRUG Phase PHASE3 CTX ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Mirum Pharmaceuticals Inc
    • Ticker Symbol: MIRM

Search

News categories